Project Details
Description
PROJECT NARRATIVE
Human T cell leukemia virus type-1 (HTLV-1) is a human retrovirus that is the causative agent of a malignant T
CD4+ cell lymphoproliferation referred to as Adult T cell leukemia/lymphoma (ATLL), as well as several
inflammatory disorders with the most problematic being human myelopathy/tropical spastic paraparesis
(HAM/TSP). Remarkable, while millions are affected worldwide, there is no effective vaccine or treatment options
to prevent ATL or HAM/TSP afflicted individuals. We thus aim here, to develop a candidate vaccine to prevent
and plausibly treat HTLV1-associated disease.
Status | Active |
---|---|
Effective start/end date | 3/3/21 → 2/28/23 |
Funding
- National Cancer Institute: $623,689.00
- National Cancer Institute: $540,678.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.